Recherche

hal-01134440v1 Article dans une revue
Marc Bourlière, Jean-Pierre Bronowicki, Victor De Ledinghen, Christophe Hézode, Fabien Zoulim et al. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS).
Lancet Infectious Diseases, Elsevier, 2015, 15 (4), pp.397-404. <10.1016/S1473-3099(15)70050-2>

hal-01142117v1 Article dans une revue
Eric Lawitz, Edward Gane, Brian Pearlman, Edward Tam, Wayne Ghesquiere et al. Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial.
Lancet, Elsevier, 2015, 385 (9973), pp.1075-86. <10.1016/S0140-6736(14)61795-5>

hal-01201948v1 Article dans une revue
Jean-Claude Trinchet, Valérie Bourcier, Cendrine Chaffaut, Mohand Ait Ahmed, Setty Allam et al. Complications and competing risks of death in compensated viral cirrhosis (ANRS CO12 CirVir prospective cohort)
Hepatology, 2015, 62 (3), pp.737--750. <10.1002/hep.27743>

inserm-00611186v1 Article dans une revue
Stéphane Chevaliez, Christophe Hézode, Alexandre Soulier, Bruno Costes, Magali Bouvier-Alias et al. High-Dose Pegylated Interferon-α and Ribavirin in Nonresponder Hepatitis C Patients and Relationship With IL-28B Genotype (SYREN Trial).
Gastroenterology, WB Saunders, 2011, 141 (1), pp.119-27. <10.1053/j.gastro.2011.03.039>

hal-01225507v1 Article dans une revue
Pierre Nahon, Mathilde Lescat, Richard Layese, Valérie Bourcier, Nabila Talmat et al. Bacterial infection in compensated viral cirrhosis impairs 5-year survival (ANRS CO12 CirVir prospective cohort)
Gut, BMJ Publishing Group, 2017, 66 (2), pp.330-341. <10.1136/gutjnl-2015-310275>

hal-01310454v1 Article dans une revue
Xavier Adhoute, Guillaume Penaranda, Jean L. Raoul, Jean F. Blanc, Julien Edeline et al. Prognosis of advanced hepatocellular carcinoma: a new stratification of Barcelona Clinic Liver Cancer stage C: results from a French multicenter study
European Journal of Gastroenterology and Hepatology, Lippincott, Williams & Wilkins, 2016, 28 (4), pp.433--440. <10.1097/MEG.0000000000000558>

hal-00827965v1 Article dans une revue
François Habersetzer, Géraldine Honnet, Christine Bain, Marianne Maynard-Muet, Vincent Leroy et al. A poxvirus vaccine is safe, induces T-cell responses, and decreases viral load in patients with chronic hepatitis C.
Gastroenterology, WB Saunders, 2011, 141 (3), pp.890-899.e1-4. <10.1053/j.gastro.2011.06.009>

hal-00866794v1 Article dans une revue
Fred Poordad, Jean-Pierre Bronowicki, Stuart C Gordon, Stefan Zeuzem, Ira M Jacobson et al. Factors that predict response of patients with hepatitis C virus infection to boceprevir.
Gastroenterology, WB Saunders, 2012, 143 (3), pp.608-18.e1-5. <10.1053/j.gastro.2012.05.011>

inserm-01057763v1 Article dans une revue
Christophe Hézode, Hélène Fontaine, Céline Dorival, Fabien Zoulim, Dominique Larrey et al. Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis.
Gastroenterology, WB Saunders, 2014, 147 (1), pp.132-142.e4. <10.1053/j.gastro.2014.03.051>

hal-00466555v1 Article dans une revue
Sébastien Blaise, Jean-Marc Alberto, Emmanuelle Nédélec, Ahmet Ayav, Grégory Pourié et al. Mild neonatal hypoxia exacerbates the effects of vitamin-deficient diet on homocysteine metabolism in rats
Pediatric Research, Nature Publishing Group, 2005, 57 (6), pp.777-82. <10.1203/01.PDR.0000161406.19231.98>

hal-00867494v1 Article dans une revue
Fred Poordad, Jonathan Mccone, Bruce R Bacon, Savino Bruno, Michael P Manns et al. Boceprevir for untreated chronic HCV genotype 1 infection.
New England Journal of Medicine, Massachusetts Medical Society, 2011, 364 (13), pp.1195-206. <10.1056/NEJMoa1010494>

inserm-00820362v1 Article dans une revue
Shannon Allen Ferrante, Jagpreet Chhatwal, Clifford Brass, Antoine El Khoury, Fred Poordad et al. Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study.
BMC Infectious Diseases, BioMed Central, 2013, 13 (1), pp.190. <10.1186/1471-2334-13-190>

hal-01414692v1 Article dans une revue
Sepolene Brichler, Richard Layese, Valérie Bourcier, Carole Cagnot, Patrick Marcellin et al. Epidemiological, clinical, biological and virological factors influencing the occurrence of hepatocellular carcinoma and validation of predictive scores in 317 HBV-related cirrhotic patients. Prospective study Cir-B nested in the ANRS CO12 CirVir cohort
Hepatology, Wiley-Blackwell, 2016, 63 (1 SUPP), pp.898A--899A

hal-01380169v1 Article dans une revue
Christophe Hézode, Victor Ledinghen, Hélène Fontaine, Fabien Zoulim, Pascal Lebray et al. Daclatasvir plus sofosbuvir with or without ribavirin in genotype 3 patients from a large French multicenter compassionate use program
Hepatology, Wiley-Blackwell, 2015, 62, pp.314A--314A

hal-01447065v1 Article dans une revue
Pierre Nahon, Valérie Bourcier, Richard Layese, Etienne Audureau, Carole Cagnot et al. Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver Complications
Gastroenterology, 2017, 152, pp.142-156.e2. <10.1053/j.gastro.2016.09.009>

hal-01494359v1 Article dans une revue
Abderrahim Oussalah, Patrice Hodonou Avogbe, Erwan Guyot, Céline Chery, Rosa-Maria Guéant et al. BRIP1 coding variants are associated with a high risk of hepatocellular carcinoma occurrence in patients with HCV- or HBV-related liver disease.
Oncotarget, Impact journals, 2016, Advance Publications 2016, <http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&page=article&op=view&path=11327&pubmed-linkout=1>. <10.18632/oncotarget.11327>

hal-01435007v1 Article dans une revue
Stanislas Pol, Marc Bourlière, Sandy Lucier, Christophe Hézode, Céline Dorival et al. Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients
Journal of Hepatology, Elsevier, 2017, 66, pp.39-47. <10.1016/j.jhep.2016.08.021>

inserm-01059165v1 Article dans une revue
Cédric Laouénan, Patrick Marcellin, Martine Lapalus, Feryel Khelifa-Mouri, Nathalie Boyer et al. Using Pharmacokinetic and Viral Kinetic Modeling To Estimate the Antiviral Effectiveness of Telaprevir, Boceprevir, and Pegylated Interferon during Triple Therapy in Treatment-Experienced Hepatitis C Virus-Infected Cirrhotic Patients.
Antimicrobial Agents and Chemotherapy, American Society for Microbiology, 2014, 58 (9), pp.5332-41. <10.1128/AAC.02611-14>

Type de document

Auteur

Domaine

Laboratoire

Langue

Type de dépôt

Année

Contact